Drug Trial Radar · NCT06967857
Clinical Trial to Investigate the Safety and Efficacy of Two Dexamfetamine Sulfate Formulations in Adults With ADHD and Moderate to Severe Depression
Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
105
Planned (sponsor's estimate)
Start
May 15, 2025
Primary completion
Mar 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Prof. Dr. Frank BehrensAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The indication of attention-deficit/hyperactivity disorder (ADHD) to be examined often occurs with other psychiatric disorders, and the majority of adults with ADHD have at least one psychiatric comorbidity in their lives. Depression is one of the most common comorbidities in patients with ADHD. The prevalence of comorbid depression in adults with ADHD is estimated to be as high as 50%. There is evidence that stimulants such as dexamfetamine and methylphenidate lead to an improvement in sustained focused attention, working memory, and a variety of cognitive processes in the prefrontal cortex (PFC). In combination with the pharmacological effects of stimulants, such as the inhibition of monoamine oxidase, the increase in the concentration of noradrenaline in the PFC and dopamine in the striatum, dexamfetamine and methylphenidate could improve the treatment of depression in patients with major depressive disorder and comorbid ADHD. This clinical trial will evaluate the safety and efficacy of DEX in two different formulations compared to placebo in adults with ADHD and moderate to severe depression. To ensure double blinding of the treatment, placebo will be administered in the form of tablets and capsules.
Conditions
- Attention-Deficit/Hyperactivity Disorder (ADHD)
- Depression - Major Depressive Disorder
Interventions
DEX IR tabletsDrug
tablet twice daily
DEX XLDrug
capsule once daily
PlaceboDrug
Placebo to either capsule or tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AE) in the active treatment groups compared to the placebo until V6Time frame: from enrollment to the end of study at week 17
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Charité - Universitätsmedizin Berlin Klinik für Psychiatrie und Psychotherapie, Campus Benjamin Franklin
Berlin, Germany · Recruiting
Universitätsklinikum Bonn AöR, Klinik und Poliklinik für Psychiatrie und Psychotherapie
Bonn, Germany · Recruiting
Department of Psychiatry, Psychosomatics and Psychotherapy University Hospital Frankfurt am Main - Goethe University
Frankfurt, Germany · Recruiting
University Leipzig, Department of Psychiatry and Psychotherapy
Leipzig, Germany · Recruiting
LMU Klinikum München Klinik für Psychiatrie und Psychotherapie
München, Germany · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.